NDA 021986 · Bristol Myers Squibb
Sprycel
Dasatinib · Oral
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jun 28, 2006
Approved uses
10
Original approval plus efficacy supplements
Registered trials
366
28 Phase 3, 24 recruiting
FAERS reports
37,260
22,458 serious, 3,748 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 16, 2026.
SPRYCEL (dasatinib) is indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. • newly diagnosed Ph+ ALL in combination with chemotherapy. SPRYCEL is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1 , 14) • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14) • pediatric patients 1 year of age and older with Ph+ CML in chronic phase. (1 , 14) • pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. (1 , 14)
Mechanism: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro , dasatinib was active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib could overcome imatinib resistance...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 21, 2018 Supplement 21 · Efficacy · priority review OrphanLabelLetterPediatric CDTL Review
- Nov 9, 2017 Supplement 20 · Efficacy · priority review OrphanLabelLetterReview
- Aug 12, 2015 Supplement 16 · Efficacy OrphanLetterLabel
- Jun 17, 2013 Supplement 13 · Efficacy LabelLetter
- Oct 28, 2010 Supplement 7 · Efficacy LabelLetter
- Oct 28, 2010 Supplement 8 · Efficacy · priority review Accelerated approvalLetterLabel
- May 21, 2009 Supplement 4 · Efficacy LetterLabel
- Nov 8, 2007 Supplement 1 · Efficacy · priority review ReviewLetter
- Nov 8, 2007 Supplement 2 · Efficacy LabelReviewLetter
- Jun 28, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
6 products under this application
- SPRYCEL · DASATINIB 80MG · TABLET, ORAL · Prescription · TE AB
- SPRYCEL · DASATINIB 70MG · TABLET, ORAL · Prescription · TE AB
- SPRYCEL · DASATINIB 20MG · TABLET, ORAL · Prescription · TE AB
- SPRYCEL · DASATINIB 140MG · TABLET, ORAL · Prescription · TE AB
- SPRYCEL · DASATINIB 100MG · TABLET, ORAL · Prescription · TE AB
- SPRYCEL · DASATINIB 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dasatinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00744497 · 1,930 participants · Start Oct 2008 · Primary completion Aug 2012
Drug: Placebo; Dasatinib and 2 more · For: Prostatic Neoplasms
Sites: Mobile, Alabama; Anchorage, Alaska; Fayetteville, Arkansas · 186 sites in all
Wei ZhaoAcademic, hospital or other
NCT03844360 · 1,500 participants (planned) · Start Jan 31, 2016 · Primary completion Dec 31, 2025
Drug: Bortezomib; Eltrombopag and 5 more · For: Hematological Neoplasms
Sites: Xuzhou, China; Tanjin, China
- Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid LeukaemiaPivotal-lookingCompleted
Newcastle UniversityAcademic, hospital or other
NCT01460693 · 814 participants · Start Aug 2008 · Primary completion Mar 7, 2018
Drug: Imatinib; Dasatinib · For: Myeloid Leukemia, Chronic, Chronic Phase
Sites: Newcastle upon Tyne, United Kingdom
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaPivotal-lookingActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT03117751 · 790 participants · Start Mar 29, 2017 · Primary completion Sep 30, 2026
Drug: Prednisone; Vincristine and 21 more · For: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
Sites: Palo Alto, California; San Diego, California; Peoria, Illinois · 8 sites in all
- A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory CancerPivotal-lookingCompleted
Institut CurieAcademic, hospital or other
NCT01771458 · 742 participants · Start Oct 2012 · Primary completion Oct 2016
Drug: Targeted therapy based on molecular profiling : Imatinib; Standard Chemotherapy and 8 more · For: Reccurent/Metastatic Solid Tumor Disease
Sites: Dijon, France; Lyon, France; Marseille, France · 8 sites in all
- Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CMLPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00123474 · 724 participants · Start Jul 2005 · Primary completion Sep 2006
Drug: dasatinib; dasatinib and 2 more · For: Myeloid Leukemia, Chronic, Chronic-Phase
Sites: Birmingham, Alabama; Alhambra, California; Anaheim, California · 137 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pleural effusion3,282
- fatigue2,554
- diarrhoea2,178
- nausea2,151
- death2,131
- headache2,014
- rash1,618
- drug ineffective1,554
- dyspnoea1,513
- adverse event1,478
- off label use1,321
- hospitalisation1,223
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 94 |
| 2007 | 313 |
| 2008 | 417 |
| 2009 | 406 |
| 2010 | 519 |
| 2011 | 522 |
| 2012 | 1,181 |
| 2013 | 1,281 |
| 2014 | 2,403 |
| 2015 | 2,571 |
| 2016 | 2,506 |
| 2017 | 2,408 |
| 2018 | 2,703 |
| 2019 | 3,279 |
| 2020 | 2,830 |
| 2021 | 2,942 |
| 2022 | 2,643 |
| 2023 | 2,739 |
| 2024 | 2,897 |
| 2025 | 1,632 |
| 2026 | 974 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sprycel (Dasatinib)
2024 spending
$518M
Beneficiaries
5,393
38,789 claims
Per beneficiary
$96,112
$438.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $418,689,356 |
| 2021 | $450,220,328 |
| 2022 | $500,484,016 |
| 2023 | $510,233,995 |
| 2024 | $518,330,507 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R, Bassan R, Vitale A, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Luskin MR, Murakami MA, Keating J, et al. · Blood 2025 · Clinical Trial, Phase I, Multicenter Study
- Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
Justice JN, Nambiar AM, Tchkonia T, et al. · EBioMedicine 2019 · Clinical Trial
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Cortes JE, Saglio G, Kantarjian HM, et al. · J Clin Oncol 2016 · Clinical Trial, Phase III, Comparative Study
- Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.
Farr JN, Atkinson EJ, Achenbach SJ, et al. · Nat Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sugiura I, Doki N, Hata T, et al. · Blood Adv 2022 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.